7,468
Views
19
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol

Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial

ORCID Icon, , , , ORCID Icon, , , , ORCID Icon, , , , , , , , , , & show all
Pages 2351-2360 | Received 26 Feb 2022, Accepted 20 Apr 2022, Published online: 05 May 2022

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.